Recognized markers for neurodegeneration, specifically Alzheimer Disease, such as cerebrospinal fluid biomarkers (amyloid-β and tau proteins concentrations) and positron emission tomography imaging (FDG and amyloid) are not available in our cohort (35). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.